Serono, Europe's biggest biotechnology company, is nearly one hundred years old. Recently, the company has been on a quest to establish a public image quite different from that of a traditional, family-owned pharmaceutical group. Driving Serono into the public eye is Ernesto Bertarelli, who took the helm from his father in 1996. The structural changes he brought about provided the framework for modernization. But Serono still has to make its mark in the US, where the most important determinant of success will be the timing of its launch of Rebif, its multiple sclerosis drug.
by Melanie A. Senior
Until recently, Serono SA was not a company many people outside Europe had heard of. Those that did know the name associated it with an old, family-run, Swiss-based pharmaceutical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
